Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia

PURPOSE: To determine the maximum-tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic profiles, and clinical activity of an oral formulation of azacitidine in patients with myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). PATIEN...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Garcia-Manero, Guillermo, Gore, Steven D., Cogle, Christopher, Ward, Renee, Shi, Tao, MacBeth, Kyle J., Laille, Eric, Giordano, Heidi, Sakoian, Sarah, Jabbour, Elias, Kantarjian, Hagop, Skikne, Barry
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2011
Témata:
Original Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3675699/
https://ncbi.nlm.nih.gov/pubmed/21576646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.34.4226
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky